WuXi Pharma Tech acquire NextCODE Health to further expand clinical genomics services.

WuXi Pharma Tech, China’s largest CRO, is expanding its genomic service with the $65 million acquisition of NextCODE Health. The company will be incorporated into WuXi’s existing sequencing operation to create a new unit. WuXi NextCODE Genomics will be headquartered in Shanghai with offices in Massachusetts and Iceland.

NextCODE Health was spun out from deCODE genetics shortly after becoming a subsidiary of Amgen. Using the deCODE genomics platform, NextCODE Health give physicians tools to identify and analyze genomic data to improve diagnoses.This technology will now be integrated with WuXi’s clinical genomics offering to build an end-to-end sequencing and analysis service.

“With the huge unmet medical needs in diseases with a genetic component and the rapid advances in genomics and bioinformatics, now is the right time for WuXi to make a strategic investment in this field, and NextCODE is the right partner,” said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. “This new venture of WuXi NextCODE Genomics will create important new genomic and bioinformatic products and services to help make personalized treatment and medicine a reality.  It will also enable doctors to provide better treatments to patients.”

“With this transaction, WuXi and NextCODE will deploy the unique advantages of their combined platform in virtually every major application of genomics worldwide,” said Hannes Smarason and Jeffrey Gulcher, co-founders of NextCODE Health. “In WuXi, we have a superior partner with strengths, including CLIA-certified sequencing and leading global pharmaceutical customers with a strong need for companion diagnostics, that are highly complementary to those of NextCODE. Together, WuXi and NextCODE have the technology, vision, and resources to be a leader in the sequencing revolution for the benefit of patients and for the advancement of medicine around the world.”


Click here for the full press release.